• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

New Delhi, Nov. 21

Ranbaxy Laboratories’ Canadian subsidiary has received marketing approval for the generic version of the benign prostatic hyperplasia (bhp) drug — Flomax. The Ontario based Ranbaxy Pharmaceuticals-Canada Inc will make and sell Tamsulosin Hydrochloride capsules of 0.4 mg. The Canadian market, for both the generic and the registered version of the drug (Flomax), is estimated at Canadian $22 million, according to Ranbaxy. The company said in a statement on Wednesd ay that it would be launching the drug immediately. Flomax is a registered trademark of Boehringer Ingelheim in Canada. Ranbaxy recently reached an out-of-court settlement with the Japanese company Astellas and the US subsidiary of Boehringer Ingelheim (BIPI) with regards to the billion dollar plus drug Flomax (Tamsulosin capsules). It now expects to launch the drug in the US in March 2010. Ranbaxy is also hopeful of a market-exclusivity for the same, on consideration of being the first to file a “complete” Paragraph IV certification.

—

Our Bureau

More Stories on : Announcements | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
MM Forgings deploys ERP solution

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line